Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ABUS | NASDAQ | USD | Real-time | |
I9DN | TradeGate | EUR | Delayed | |
I9DN | Frankfurt | EUR | Delayed |
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Frank M. Torti | 42 | 2018 | Independent Chairman of the Board of Directors |
Kyong-Mi Chang | - | - | Member of Scientific Advisory Board |
Ulrike Protzer | - | - | Member of Scientific Advisory Board |
Adrian Di Bisceglie | - | - | Member of Scientific Advisory Board |
Keith S. Manchester | 56 | 2015 | Independent Non-Executive Director |
William T. Symonds | 56 | 2015 | Chairman of Scientific Advisory Board |
Fabien Zoulim | - | - | Member of Scientific Advisory Board |
James R. Meyers | 59 | 2018 | Independent Director |
Daniel D. Burgess | 62 | 2017 | Independent Director |
Charles M. Rice | - | - | Member of Scientific Advisory Board |
Scott A. Biller | 68 | - | Member of Scientific Advisory Board |
Richard C. Henriques | 68 | 2014 | Independent Non-Executive Director |
Michael J. McElhaugh | 49 | 2018 | Co-Founder, Interim President, CEO & Director |
Melissa V. Rewolinski | 53 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review